Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice
2019
Objectives. Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3
(G3) treatments continue to be a challenge, mainly in cirrhotic
patients. The aim of this study is to analyse effectiveness and
safety of daclatasvir associated with sofosbuvir with or without
ribavirin in G3-HCV infected patients in real clinical practice.
Patients and methods. An observational, prospective,
cohort study over 2.5 years, in G3-HCV infected adult patients,
in all fibrosis stages including patients with decompensated
cirrhosis. Treatment was a combination of sofosbuvir 400 mg/
day + daclatasvir 60 mg/day, with or without a weight-adjusted dosing of ribavirin for 12 or 24 weeks. The primary efficacy
endpoint was sustained virologic response rates 12 weeks after
therapy (SVR12). The primary safety endpoint was treatment
withdrawal rates secondary to severe adverse events.
Results. A total of 111 patients were enrolled, 32.4% cirrhotics and 29.9% treatment-experienced. The global SVR12 rate
was 94.6%, while the SVR12 rate in F3-4 fibrosis stage patients
was 90.8% versus 100% in patients with F0-2 fibrosis (p=0.03).
In cirrhotic patients, SVR12 was 100% versus 40% depending
on whether ribavirin was added or not to daclatasvir/sofosbuvir
(p=0.001). No other patient or treatment basal variables influenced the treatment effectiveness. No patient treatment withdrawal secondary to severe adverse events was observed.
Conclusions. Daclatasvir/sofosbuvir ± ribavirin is highly
effective in G3-HCV infected patients. Advanced degrees of
fibrosis significantly decrease the effectiveness of this treatment, which motivates the need for the addition of ribavirin
in cirrhotic patients. The regimen was safe and well tolerated.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
28
References
5
Citations
NaN
KQI